Process for the production of immunogenic compositions
AssigneeGlaxosmithkline Biologicals SA
InventorsTeresa Cabezon Silva, Joseph Cohen, Moncef Mohamed Slaoui, Carlota Vinals Bassols
Life of this patent
Estimating the term…
Abstract
The present invention relates to a process for producing immunogenic polypeptides, comprising reducing disulfide bonds and blocking the resulting free thiol group with a blocking agent. The immunogenic peptides comprise a fragment of MAGE A3.
Claims28
A process for the production of an immunogenic MAGE A3 polypeptide, comprising the steps of:
- a. treating a MAGE A3 polypeptide consisting of a sequence corresponding to amino acids 130-441 of SEQ ID NO:2 to reduce a disulfide bond and produce a free thiol group;
- b. blocking said free thiol group with a blocking agent;
- and
- c. purifying a polypeptide resulting from step (ii) using one or more chromatographic purification steps,
where the purified polypeptide is immunogenic and contains said blocking agent.
A process for the production of an immunogenic composition, comprising the steps of:
- a. treating a MAGE A3 polypeptide consisting of a sequence corresponding to amino acids 130-441 of SEQ ID NO:2 to reduce a disulfide bond and produce a free thiol group;
- b. blocking said free thiol group with a blocking agent;
- and
- c. purifying a polypeptide resulting from step (ii) using one or more chromatographic purification steps;
- and
- d. formulating a polypeptide resulting from step (iii) as a pharmaceutical composition, where the purified polypeptide is immunogenic and contains said blocking agent.
A polypeptide comprising a MAGE A3 polypeptide and a heterologous fusion partner to form a fusion protein, where the MAGE A3 polypeptide consists of a sequence corresponding to amino acids 130-441 of SEQ ID NO:2, and where the cysteine residues in said fusion protein contain free thiol groups blocked by a blocking agents, such that the cysteine residues do not form disulfide bonds.
Dependencies are inferred from the claim text.